Is MEDVi Legit? The Highest-Rated GLP-1 Weight Loss Platform Reviewed

Yes, MEDVi is a legitimate telehealth company that has been operating since 2022. Headquartered in Orlando, FL, MEDVi provides treatments in Weight Loss, serving patients across the United States through licensed healthcare providers. MEDVi offers one of the most complete weight loss programs in telehealth, combining GLP-1 medication with a metabolic health platform that includes body composition tracking, nutrition coaching, and ongoing provider consultations — all at a single monthly price. You can check MEDVi's current rating and complaint record at the Better Business Bureau.

Founded in 2022, MEDVi has attracted investor confidence in the competitive telehealth market, securing the funding needed to build out their technology platform, provider network, and pharmacy partnerships. While newer than some established competitors, MEDVi's business model has been validated by venture capital due diligence processes that evaluate regulatory compliance, market opportunity, and operational capability. All providers on the platform must maintain active licenses verified through state medical boards.

You can read independent patient reviews on Trustpilot alongside our own editorial rating. Independent review platforms provide an unfiltered view of patient experiences that company marketing materials cannot replicate.

MEDVi offers treatments across 1 category: Weight Loss. This focused specialization allows the company to concentrate its medical expertise, technology investment, and customer service resources on a single treatment area, potentially delivering deeper expertise than broader platforms. The company's treatment offerings match standard telehealth practice in their respective categories.

MEDVi follows a structured telehealth process designed to deliver prescription treatment safely and conveniently. You begin on MEDVi's website by completing an in-depth metabolic health assessment that goes beyond standard weight and BMI — it includes body composition questions, metabolic health history, lifestyle factors, and treatment goals. A physician specialized in obesity medicine reviews your assessment and creates a personalized treatment protocol. You are matched with a dedicated coaching team that provides ongoing support alongside your medication. Monthly provider check-ins use body composition tracking data to guide dose adjustments and measure metabolic improvements.

The initial health assessment is a critical component of the MEDVi process, serving as the foundation for safe prescribing decisions. Telehealth health assessments must collect sufficient information for providers to make informed prescribing decisions without an in-person examination. This includes current medications, allergies, relevant medical history, and contraindication screening specific to the requested treatment. Patients should answer all health questions honestly and completely, as inaccurate information could lead to inappropriate prescriptions or missed safety concerns. The Ryan Haight Act requires that telehealth prescribers maintain appropriate provider-patient relationships for controlled substance prescribing.

Once a provider approves your treatment, MEDVi coordinates prescription fulfillment through their pharmacy network. MEDVi partners with FDA-registered compounding pharmacies that prepare compounded semaglutide and tirzepatide under cGMP standards. Each medication batch undergoes potency and sterility testing. Their pharmacy partners are independently audited and maintain current state and federal pharmacy licensing. MEDVi's complete approach includes pharmacy team coordination with clinical providers for dosing adjustments. The prescription-to-delivery timeline varies based on medication type and shipping method, but patients can generally expect to receive their first order within one to two weeks of initial consultation approval. Subsequent refills are typically faster as the pharmacy already has your prescription on file. All pharmacy partners must comply with state board of pharmacy regulations.

Follow-up care is an essential component of responsible telehealth practice, and MEDVi provides ongoing access to licensed providers after the initial consultation. For ongoing treatments, MEDVi schedules regular provider check-ins to monitor treatment efficacy, manage side effects, and adjust dosing as needed. This follow-up cadence is particularly important for treatments with dose-escalation protocols, such as GLP-1 weight loss medications, where provider oversight at each dose increase is a standard safety requirement. The HHS telehealth policy framework outlines best practices for ongoing telehealth care management.

MEDVi ships GLP-1 medications in temperature-controlled packaging from their compounding pharmacy partners with free standard shipping. Most orders arrive within 5-7 business days, and monthly refills are coordinated with your dose schedule. All medications are shipped in discreet packaging with no visible treatment information on the exterior, protecting patient privacy during delivery. Patients should ensure they provide accurate shipping information and are available to receive temperature-sensitive medications promptly, as some treatments (particularly injectable GLP-1 medications) require proper storage upon arrival. For information on HIPAA protections covering your health data during the shipping process, refer to the privacy section below.

Yes, MEDVi uses real, licensed healthcare providers for all medical consultations and prescriptions. MEDVi employs physicians specialized in obesity medicine and metabolic health. Each patient receives a dedicated provider plus access to their coaching team. Providers conduct detailed metabolic assessments rather than simple BMI-based screening, creating more personalized treatment protocols. All providers on the MEDVi platform must maintain active, unrestricted medical licenses in the states where they practice, which can be independently verified through state medical board databases.

State medical licensing is the primary safeguard ensuring telehealth provider quality. Each state maintains a medical board that issues, renews, and monitors physician licenses, and patients can verify any provider's license status through these public databases maintained by the Federation of State Medical Boards. MEDVi is responsible for verifying that every provider on their platform holds current, unrestricted licenses in the states where they treat patients. This verification process includes confirming medical school graduation, residency completion, board certification status through the American Board of Medical Specialties, and absence of disciplinary actions. Patients who wish to verify their provider's credentials independently can search the FSMB's DocInfo database or their specific state's medical board website.

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 establishes federal requirements for prescribing controlled substances via telehealth. This law requires that at least one in-person or qualifying telehealth evaluation occur before a controlled substance can be prescribed. For non-controlled medications (which constitute the majority of treatments prescribed by platforms like MEDVi), standard telehealth prescribing regulations apply. These regulations require providers to conduct an adequate evaluation, establish a provider-patient relationship, and maintain appropriate medical records. The DEA has established specific pathways for telehealth prescribing that MEDVi must follow.

MEDVi's provider model emphasizes specialization in Weight Loss, which means their physicians and nurse practitioners develop concentrated expertise in the specific conditions they treat. This focused approach can lead to better patient outcomes, as providers who treat the same conditions daily develop pattern recognition and nuanced clinical judgment that generalists may lack. Patients should feel empowered to ask their MEDVi provider about their specific qualifications and experience with the requested treatment. Provider board certifications can be verified at the ABMS.

Patients can take several steps to verify the legitimacy of their healthcare provider, whether through MEDVi or any telehealth platform. First, check the provider's license status through the state medical board where they practice. Second, verify their National Provider Identifier (NPI) through the NPPES NPI Registry at npiregistry.cms.hhs.gov. Third, check for any disciplinary actions through the National Practitioner Data Bank. Fourth, confirm board certification through the American Board of Medical Specialties at certificationmatters.org. These verification steps are free, publicly accessible, and provide independent confirmation of a provider's credentials beyond what any telehealth platform reports.

MEDVi prescribes compounded medications, which are prepared by FDA-registered compounding pharmacies rather than manufactured by pharmaceutical companies. This is an important distinction: while the active pharmaceutical ingredients in compounded medications are FDA-approved, the specific compounded formulations have not undergone individual FDA clinical trials. This is standard practice for all compounded medications across the healthcare industry — not unique to MEDVi — and is regulated under federal and state pharmacy law.

Compounding pharmacies operate under two primary regulatory categories: 503A and 503B. Section 503A pharmacies compound individual patient prescriptions based on a licensed prescriber's order — these are traditional compounding operations similar to what hospital pharmacies have done for decades. Section 503B pharmacies are outsourcing facilities that can compound in larger batches and must register with the FDA, follow current Good Manufacturing Practice (cGMP) standards, and submit to FDA inspection. MEDVi's pharmacy partners operate under these regulatory frameworks with appropriate state and federal oversight.

MEDVi partners with FDA-registered compounding pharmacies that prepare compounded semaglutide and tirzepatide under cGMP standards. Each medication batch undergoes potency and sterility testing. Their pharmacy partners are independently audited and maintain current state and federal pharmacy licensing. MEDVi's complete approach includes pharmacy team coordination with clinical providers for dosing adjustments. Quality control in pharmaceutical dispensing involves multiple checkpoints: verification of prescription accuracy, drug interaction screening, patient allergy checks, and proper medication storage and handling. For compounded medications specifically, potency testing verifies that the correct amount of active ingredient is present in each dose, and sterility testing (for injectable medications like GLP-1s) confirms the absence of microbial contamination. These tests are performed on each batch before any medication is dispensed to patients.

Patients should understand the regulatory market of their specific medications when evaluating any telehealth platform. For compounded medications like those offered by MEDVi, the key questions to ask are: Is the compounding pharmacy FDA-registered? Do they follow cGMP standards? Do they test each batch for potency and sterility? Are they licensed by their state board of pharmacy? Affirmative answers to these questions indicate a compliant compounding operation. Patients can verify pharmacy registration through the FDA's database.

The broader telehealth medication market is evolving, with the FDA, DEA, and state pharmacy boards continuously updating regulations to address new delivery models. MEDVi operates within this regulatory framework, and patients can independently verify compliance through public databases maintained by the FDA (pharmacy registration), DEA (controlled substance licensing), and state boards of pharmacy (dispensing authorization). These verification tools are freely available online and provide patients with the means to confirm that their medication source meets all applicable regulatory standards.

MEDVi holds a 9.2 (Outstanding) rating in our ratings.

You can read current, unfiltered patient feedback on Trustpilot, and recent reviews deserve more weight than older ones. We do not quote third-party review statistics we cannot verify; our own 9.2 (Outstanding) rating reflects our editorial assessment of pricing, transparency, and service quality.

A MEDVi review earns its weight from its date and its subject. Recent entries describe the program as it runs today, while older ones may describe plans and prices that have moved since. The ratings spread is the second read, since a page swinging between five stars and one star says something different from one gathered at four. MEDVi charges no cancellation fee but does not refund medication once it has shipped, so the accounts worth the most to you are the ones describing how a plan ended rather than how it started.

Common positive themes in MEDVi reviews include complete metabolic health, GLP-1 + coaching platform, body composition tracking, and the effectiveness of treatments offered. These positive patterns are consistent with the platform's stated value proposition and suggest that MEDVi delivers on its core promises for the majority of patients. However, no telehealth platform achieves 100% satisfaction, and understanding the common complaints is equally important for setting realistic expectations.

Independent review platforms like Trustpilot and the Better Business Bureau provide unfiltered patient feedback that company marketing cannot replicate. We recommend checking these sources directly before making a healthcare decision, paying particular attention to reviews from the past 6 months and filtering for reviews that discuss your specific treatment category. You can check the company's current BBB profile directly for complaint history and responsiveness.

MEDVi's pricing is structured as follows: Weight Loss Program: from $149/month. Includes: medication, coaching, tracking, consultations. These prices represent the platform's current listed rates and include the base cost of treatment. Whether additional fees apply depends on the specific treatment plan and payment structure. Understanding the complete cost picture requires examining not just the headline price but also consultation fees, shipping costs, and any recurring charges.

MEDVi is cash-pay only but their all-inclusive pricing covers medication, provider consultations, coaching, and tracking tools — no hidden fees. HSA/FSA payments are accepted.. For GLP-1 weight loss treatment specifically, compounded semaglutide and tirzepatide pricing at telehealth platforms reflects the cost of compounding pharmacy preparation, provider consultations, and ongoing monitoring, not just the active ingredient. Brand-name GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) are cheaper to self-pay than they used to be: Novo Nordisk's NovoCare Pharmacy lists Wegovy at $199 a month for your first two fills and $349 a month after that, and Lilly's LillyDirect lists the Zepbound KwikPen or vial at $299 a month, both verified September 2026. Compare any compounded plan against those cash prices rather than against an insurer list price.

Hidden fee analysis: MEDVi does not charge cancellation fees. Based on our analysis and patient review data, MEDVi's pricing is generally transparent with the listed rates reflecting the actual out-of-pocket cost. Patients should confirm the total cost during their consultation, including any ancillary fees for shipping upgrades, expedited processing, or add-on services.

Payment options at MEDVi include standard credit and debit cards. HSA (Health Savings Account) and FSA (Flexible Spending Account) payments are accepted for eligible treatments, which can provide tax advantages of 20-35% depending on your tax bracket. To use HSA/FSA funds, patients typically need to pay with their HSA/FSA debit card or submit receipts for reimbursement. Some platforms also offer financing options through third-party providers like Affirm or CareCredit for patients who prefer to spread payments over several months.

When comparing MEDVi's pricing to competitors, it is important to compare equivalent services rather than just headline numbers. A lower per-month price that excludes consultation fees, shipping, or dose adjustment charges may not be cheaper than a higher all-inclusive price. MEDVi's pricing is designed to be all-inclusive, covering medication, consultations, and shipping in a single monthly price. We recommend requesting a complete cost breakdown before starting treatment with any telehealth platform.

MEDVi is cash-pay only but their all-inclusive pricing covers medication, provider consultations, coaching, and tracking tools — no hidden fees. HSA/FSA payments are accepted. Because MEDVi does not bill insurance, you pay the listed cash price and there is no claim to submit.

For patients with Health Savings Accounts (HSA) or Flexible Spending Accounts (FSA), MEDVi accepts these payment methods for eligible treatments. HSA and FSA accounts allow patients to pay for qualified medical expenses with pre-tax dollars, effectively reducing the cost by 20-35% depending on the patient's tax bracket. Detailed information about health savings and flexible spending accounts and eligible expenses is available from the IRS in Publication 969. Understanding the tax-advantaged payment options available can significantly change the real cost of treatment.

MEDVi's insurance coordination process works as follows: during signup, you provide your insurance information, and MEDVi verifies your coverage and benefits. For covered services, MEDVi submits claims directly to your insurance company, and you are responsible for any copay, coinsurance, or deductible amounts based on your plan. Processing times vary by insurer but typically take 1-2 weeks for verification. If your insurance does not cover a specific treatment, MEDVi offers cash-pay alternatives at their listed prices.

Patients considering MEDVi should also explore manufacturer savings programs, patient assistance programs, and generic alternatives that can reduce out-of-pocket costs regardless of insurance status. For weight loss specifically, brand-name GLP-1 manufacturers (Novo Nordisk for Wegovy/Ozempic, Eli Lilly for Zepbound/Mounjaro) offer savings cards for commercially insured patients that can reduce copays significantly. Compounded alternatives like those offered by many telehealth platforms provide a more affordable option for patients without GLP-1 insurance coverage.

The insurance market for telehealth is evolving rapidly, with more insurers covering virtual visits following pandemic-era policy changes as outlined by HHS telehealth policy. MEDVi's existing insurance acceptance positions them well as coverage expands. Patients should periodically check with their insurer about new telehealth benefits, as plans update coverage annually. The American Telemedicine Association tracks federal and state telehealth policy activity. The Consolidated Appropriations Act of 2023 extended telehealth flexibilities through 2025, and legislative proposals are underway to make many of these provisions permanent.

Cancelling costs no fee, but your request has to reach MEDVi at least 72 hours before your next billing date or the next cycle is charged. MEDVi offers both monthly and prepaid plans. Prepaid plans offer discounts but unused portions are not refunded upon early cancellation.. Understanding the cancellation process before signing up is essential for avoiding unexpected charges. MEDVi's cancellation policy is designed to give patients flexibility, though the specific terms depend on whether you're on a monthly, quarterly, or annual plan.

Monthly plans cancel anytime with no fee, provided your request reaches MEDVi at least 72 hours before the next billing date. Prepaid plans continue through the paid period but aren't refunded early. Shipped medications are non-refundable. Contact support for billing concerns.. Telehealth medication refunds are generally limited once medications have been shipped due to pharmaceutical regulations that prevent the resale or redistribution of dispensed medications. This is an industry-wide standard, not specific to MEDVi. Patients should treat the first month of any telehealth subscription as a commitment and cancel before the next billing cycle if they decide the service is not right for them.

For patients considering MEDVi, we recommend the following approach to manage subscription risk. First, start with a monthly plan rather than committing to a quarterly or annual plan upfront — monthly plans cost slightly more per month but provide maximum cancellation flexibility. Second, set a calendar reminder 3-5 days before your billing date to evaluate whether you want to continue. Third, document your cancellation if you choose to cancel — take screenshots of the confirmation and note the date, method, and any reference numbers provided. These steps protect you regardless of which telehealth platform you use.

If you experience a billing dispute with MEDVi, you have several resolution paths available. First, contact MEDVi's customer support directly — most billing issues can be resolved at this level. Second, if direct resolution fails, file a complaint with the Better Business Bureau, which facilitates mediated dispute resolution. Third, dispute the charge with your credit card company or bank under the Fair Credit Billing Act, which provides consumer protections for unauthorized or disputed charges. Fourth, for systemic issues, file a complaint with your state's attorney general consumer protection division or the Federal Trade Commission.

MEDVi's metabolic health approach means more thorough baseline assessment than medication-only platforms — they evaluate metabolic markers, body composition, and health history before prescribing GLP-1 medications. Their dose titration is guided by individual metabolic response, not just a standard schedule. Provider monitoring includes tracking metabolic health improvements alongside weight loss.. Every medication and supplement carries potential side effects, and understanding these risks is a critical component of informed healthcare decision-making. The side effects associated with MEDVi's treatments are well-documented in medical literature and are not unique to the telehealth delivery model — the same medications prescribed at a traditional doctor's office carry identical risk profiles. Complete drug safety information is available through the FDA's drug safety portal.

GLP-1 receptor agonist medications (semaglutide and tirzepatide) carry well-documented side effects that patients should anticipate. According to published clinical research, the most common side effects are gastrointestinal: nausea (affecting approximately 44% of patients in the first month), vomiting (24%), diarrhea (30%), and constipation (24%). These GI effects are typically dose-dependent and most severe during the initial weeks and at each dose escalation step. Clinical trial data demonstrates that GI side effects generally diminish significantly by week 8-12 as the body adapts. Tirzepatide studies show similar GI patterns with the dual GIP/GLP-1 mechanism. Serious but rare risks include pancreatitis, gallbladder disease, and a theoretical risk of medullary thyroid carcinoma based on rodent studies (which is why personal or family history of MTC is an absolute contraindication).

MEDVi's providers are responsible for screening patients for contraindications before prescribing any treatment, following guidelines established by state medical boards and the Ryan Haight Act. This screening process includes reviewing medical history for conditions that contraindicate treatment, checking current medications for potential drug interactions, and assessing individual risk factors such as age, cardiovascular health, and organ function. Patients who experience unexpected or severe side effects should contact their provider immediately and seek emergency medical attention for symptoms such as chest pain, difficulty breathing, severe allergic reactions, or signs of pancreatitis (persistent severe abdominal pain).

Long-term safety data varies by medication class. GLP-1 receptor agonists have approximately 10 years of post-market data for diabetes. Semaglutide was FDA-approved for diabetes in 2017 and for weight loss in 2021, with ongoing long-term cardiovascular outcomes studies (SELECT trial) providing additional safety data. Ongoing post-market surveillance by the FDA monitors for rare adverse events that may not appear in clinical trials.

Patients should maintain an open line of communication with their MEDVi provider regarding any side effects experienced during treatment. Reporting side effects allows providers to adjust dosing, switch medications, or add supportive treatments to manage symptoms. Patients can also report adverse events directly to the FDA through MedWatch (fda.gov/medwatch), which contributes to the post-market surveillance system that protects all patients. Documentation of side effects — including onset timing, severity, duration, and any actions taken — helps providers make informed treatment decisions.

MEDVi is HIPAA compliant with encrypted data storage. Their metabolic health tracking collects additional body composition data that simpler platforms don't — patients should review what data is collected and how it's used. Patient health data is not sold to third parties.. As a telehealth platform handling protected health information (PHI), MEDVi is subject to the Health Insurance Portability and Accountability Act (HIPAA), which establishes national standards for the protection of individually identifiable health information. Patient data protection is a critical concern in digital healthcare, where sensitive health information is transmitted and stored electronically.

HIPAA's Privacy Rule (45 CFR Part 164) governs how covered entities and their business associates handle protected health information. For MEDVi, this means implementing administrative safeguards (workforce training, access controls, audit procedures), physical safeguards (facility access controls, device security), and technical safeguards (encryption, access controls, audit logs). Violations of HIPAA can result in civil penalties ranging from $100 to $50,000 per violation (up to $1.5 million per year for repeated violations) and criminal penalties including imprisonment for knowing violations. These regulatory frameworks provide meaningful protection for patient information.

MEDVi's data collection practices include medical history, current medications, health questionnaire responses, provider communications, prescription records, payment information, and usage analytics. Patients should review MEDVi's privacy policy (available on their website) to understand specifically what data is collected, how it is used, who it is shared with, and how long it is retained. Key privacy policy provisions to look for include: whether health data is sold to third parties, whether data is shared with advertising networks, and what happens to your data if you cancel your account. The HealthIT.gov telehealth resource provides additional guidance on evaluating telehealth privacy practices.

MEDVi's data security practices should include, at minimum, encryption of data in transit (HTTPS/TLS) and at rest, multi-factor authentication for employee access to patient records, regular security audits, and an incident response plan for potential data breaches. Patients can ask MEDVi's support team about specific security certifications (such as SOC 2 Type II, HITRUST, or ISO 27001) that independently validate their data security infrastructure. HIPAA requirements set the baseline for these protections.

Patients have specific rights regarding their health data under HIPAA and state privacy laws. These include the right to access your medical records, the right to request corrections to inaccurate information, the right to receive an accounting of disclosures (who your data has been shared with), and the right to request restrictions on certain uses of your information. If you believe your privacy has been violated, you can file a complaint with the HHS Office for Civil Rights (hhs.gov/ocr) or your state's attorney general. For MEDVi patients, exercising these rights typically involves contacting their support team or privacy officer as described in their privacy policy.

MEDVi offers the best balance of completeness and price in GLP-1 weight loss. At $149/month with coaching, tracking, and dedicated providers, you get significantly more than medication-only platforms (Hims) without the premium pricing of Calibrate ($199+). Consistent feedback across independent platforms is the signal to look for; check current reviews before enrolling. For patients who want more than just medication delivery but don't want to pay premium prices — MEDVi is the sweet spot.. This assessment is based on analyzing MEDVi's pricing structure, provider credentials, patient review patterns on Trustpilot, regulatory compliance, and competitive positioning against alternative platforms. Every telehealth platform has strengths and limitations, and the right choice depends on your individual needs, budget, and treatment preferences.

MEDVi is best suited for: patients specifically seeking Weight Loss treatment who value a platform with deep specialization in their condition. Their key differentiators include complete metabolic health, GLP-1 + coaching platform, body composition tracking, which position them uniquely in the telehealth market. Patients whose needs align with these strengths will likely have the best experience with MEDVi.

Key strengths: complete metabolic health; GLP-1 + coaching platform; body composition tracking. Key limitations: limited to a single treatment category, requiring additional platforms for other health needs; the standard telehealth limitation of no in-person physical examination. These limitations are common across the telehealth industry and do not indicate problems specific to MEDVi.

Overall rating: 9.2 (Outstanding) in our editorial ratings, based on regulatory compliance verification, pricing analysis, and provider credentialing review. We update our assessments regularly based on new patient review data, regulatory changes, and platform updates.

Before starting treatment with MEDVi or any telehealth platform, we recommend the following steps. First, verify that your specific condition and desired treatment are available through the platform. Second, check current pricing directly on medvihq.com as rates may change. Third, review the platform's privacy policy to understand how your health data will be used per HIPAA guidelines. Fourth, prepare to answer health assessment questions honestly and completely. Fifth, keep your primary care physician informed about any telehealth treatments you begin. Verify provider credentials through the FSMB and ABMS. Informed patients who take these preparatory steps consistently report the highest satisfaction with telehealth services.